Revolutionizing Alzheimer's disease and clinical trials through biomarkers

Niklas Mattsson, Maria C. Carrillo, Robert A. Dean, Michael D. Devous, Tania Nikolcheva, Pedro Pesini, Hugh Salter, William Z. Potter, Reisa S. Sperling, Randall J. Bateman, Lisa J. Bain, Enchi Liu

Research output: Contribution to journalReview articlepeer-review

78 Scopus citations


The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.

Original languageEnglish (US)
Pages (from-to)412-419
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Issue number4
StatePublished - Dec 1 2015


  • Alzheimer's disease
  • Amyloid
  • Biomarkers
  • Blood biomarkers
  • CSF
  • Cerebrospinal fluid
  • Clinical trials
  • Imaging
  • MRI
  • PET
  • Tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Revolutionizing Alzheimer's disease and clinical trials through biomarkers'. Together they form a unique fingerprint.

Cite this